# Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

> **NCT02854605** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 140 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** GS-9674
- **DRUG:** Placebo to match GS-9674

## Key facts

- **NCT ID:** NCT02854605
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-26
- **Primary completion:** 2018-01-09
- **Final completion:** 2018-01-09
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2019-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02854605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02854605, "Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02854605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*